Brief: Transgene And BioInvent Joint JITC Publication Shows Potential Of BT-001 Oncolytic Virus

BioInvent International AB

20/01/2022 07:13

Jan 20 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE AND BIOINVENT JOINT JITC PUBLICATION
DEMONSTRATES THE
POTENTIAL OF BT-001 ONCOLYTIC VIRUS TO PROVIDE THERAPEUTIC
BENEFIT BEYOND CURRENT ANTI-PD1/ ANTI-CTLA-4 IMMUNE CHECKPOINT
BLOCKADE
    * RECRUITMENT IN THE ONGOING PHASE I/IIA CLINICAL STUDY OF
BT-001
(NCT04725331)IN EUROPE IS PROGRESSING STEADILY
    * THE TRIAL ASSESSES BT-001 AS A SINGLE AGENT AND IN
COMBINATION
WITH THE PD-1 CHECKPOINT INHIBITOR PEMBROLIZUMAB AGAINST SOLID
TUMORS
    * INITIAL PHASE I DATA ARE EXPECTED IN THE FIRST HALF OF
2022

Source text for Eikon:  ID:nBw9MMksBa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))